← FDA DRUG APPROVALS

FDA ANDA · ANDA211586

BUPRENORPHINE

Sponsor: AMNEAL

APPLICATION
ANDA211586
TYPE
ANDA
ORIGINAL APPROVAL
2020-04-14
LATEST ACTION
2026-06-18
ROUTE
TRANSDERMAL
DOSAGE FORM
FILM, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

BUPRENORPHINEPrescription
BUPRENORPHINE 20MCG/HR · FILM, EXTENDED RELEASE · TRANSDERMAL
BUPRENORPHINEPrescription
BUPRENORPHINE 10MCG/HR · FILM, EXTENDED RELEASE · TRANSDERMAL
BUPRENORPHINEPrescription
BUPRENORPHINE 5MCG/HR · FILM, EXTENDED RELEASE · TRANSDERMAL
BUPRENORPHINEPrescription
BUPRENORPHINE 15MCG/HR · FILM, EXTENDED RELEASE · TRANSDERMAL
BUPRENORPHINEPrescription
BUPRENORPHINE 7.5MCG/HR · FILM, EXTENDED RELEASE · TRANSDERMAL

Approval history

2026-06-18REMS · Supplement 19AP
2024-10-31REMS · Supplement 14AP
2024-05-30Labeling · Supplement 16 · standardAP
2024-05-30Labeling · Supplement 10 · standardAP
2024-05-30Labeling · Supplement 6 · standardAP
2021-02-02Labeling · Supplement 3 · standardAP
2020-04-14UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →